HC Wainwright Comments on Eyenovia FY2029 Earnings

Eyenovia, Inc. (NASDAQ:EYEN) – Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Eyenovia in a report issued on Thursday, February 6th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings of $1.40 per share for the year. HC Wainwright has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Eyenovia’s current full-year earnings is ($0.52) per share.

Eyenovia (NASDAQ:EYEN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($8.80) EPS for the quarter, topping analysts’ consensus estimates of ($10.40) by $1.60. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same quarter in the prior year, the business posted ($14.40) earnings per share.

Several other brokerages have also recently commented on EYEN. LADENBURG THALM/SH SH reiterated a “neutral” rating on shares of Eyenovia in a research report on Monday, November 18th. William Blair reissued a “market perform” rating on shares of Eyenovia in a research report on Friday, November 15th. Finally, Brookline Capital Management restated a “hold” rating on shares of Eyenovia in a research report on Friday, November 15th.

Eyenovia Stock Performance

Shares of NASDAQ:EYEN opened at $1.80 on Friday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.55 and a current ratio of 0.74. The firm has a market cap of $2.51 million, a PE ratio of -2.47 and a beta of 1.24. Eyenovia has a twelve month low of $1.80 and a twelve month high of $205.60. The business has a fifty day moving average of $6.67 and a 200-day moving average of $33.30.

Hedge Funds Weigh In On Eyenovia

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its position in Eyenovia by 36.6% during the 3rd quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock worth $288,000 after buying an additional 149,471 shares during the period. Nations Financial Group Inc. IA ADV increased its position in Eyenovia by 78.6% during the third quarter. Nations Financial Group Inc. IA ADV now owns 90,900 shares of the company’s stock worth $47,000 after acquiring an additional 40,000 shares during the period. Finally, Financial Management Network Inc. acquired a new stake in Eyenovia in the 3rd quarter worth about $39,000. 25.84% of the stock is owned by institutional investors.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.